Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
- PMID: 28335509
- PMCID: PMC5372679
- DOI: 10.3390/ijms18030667
Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of reasons including very late diagnosis. This in part is due to the lack of understanding of the biological behavior of PDAC and the ineffective screening for this disease. Significant efforts have been dedicated to finding the appropriate serum and imaging biomarkers to help early detection and predict response to treatment of PDAC. Carbohydrate antigen 19-9 (CA 19-9) has been the most validated serum marker and has the highest positive predictive value as a stand-alone marker. When combined with carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA 125), CA 19-9 can help predict the outcome of patients to surgery and chemotherapy. A slew of novel serum markers including multimarker panels as well as genetic and epigenetic materials have potential for early detection of pancreatic cancer, although these remain to be validated in larger trials. Imaging studies may not correlate with elevated serum markers. Critical features for determining PDAC include the presence of a mass, dilated pancreatic duct, and a duct cut-off sign. Features that are indicative of early metastasis includes neurovascular bundle involvement, duodenal invasion, and greater post contrast enhancement. 18-F-fluorodeoxyglucose (18-FDG) radiotracer uptake and changes following treatment may predict patient overall survival following treatment. Similarly, pretreatment apparent diffusion coefficient (ADC) values may predict prognosis with lower ADC lesions having worse outcome. Although these markers have provided significant improvement in the care of pancreatic cancer patients, further advancements can be made with perhaps better combination of markers or discovery of unique marker(s) to pancreatic cancer.
Keywords: biomarker; imaging; pancreatic ductal adenocarcinoma; serum.
Conflict of interest statement
John Chang has no conflict of interest to disclose. Madappa Kundranda has served on the advisory board and speaker bureau for Celgene, Amgen, and Bayer.
Figures

Similar articles
-
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23. Int J Surg. 2013. PMID: 24161419
-
Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.Surg Today. 2014 Sep;44(9):1692-701. doi: 10.1007/s00595-013-0752-9. Epub 2013 Oct 9. Surg Today. 2014. PMID: 24114022
-
Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.Biomarkers. 2020 Mar;25(2):186-193. doi: 10.1080/1354750X.2020.1725786. Epub 2020 Feb 13. Biomarkers. 2020. PMID: 32009482
-
Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.ANZ J Surg. 2017 Dec;87(12):987-992. doi: 10.1111/ans.14131. Epub 2017 Aug 13. ANZ J Surg. 2017. PMID: 28803454 Review.
-
Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?South Med J. 2014 Apr;107(4):256-63. doi: 10.1097/SMJ.0000000000000088. South Med J. 2014. PMID: 24937521 Review.
Cited by
-
Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer.Int J Mol Sci. 2020 Aug 27;21(17):6193. doi: 10.3390/ijms21176193. Int J Mol Sci. 2020. PMID: 32867211 Free PMC article.
-
Diagnosis of colorectal cancer based on folate receptor-positive circulating tumor cell analysis: a retrospective cohort study.Int J Clin Oncol. 2024 Feb;29(2):149-158. doi: 10.1007/s10147-023-02435-6. Epub 2023 Dec 19. Int J Clin Oncol. 2024. PMID: 38112831
-
Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now.Medicine (Baltimore). 2018 Aug;97(35):e12132. doi: 10.1097/MD.0000000000012132. Medicine (Baltimore). 2018. PMID: 30170450 Free PMC article. Review.
-
Serum High-Density Lipoprotein Cholesterol Concentrations in Pancreatic Ductal Adenocarcinoma and Its Association With Histological Grade in a Chinese Population.Cancer Control. 2025 Jan-Dec;32:10732748251316602. doi: 10.1177/10732748251316602. Cancer Control. 2025. PMID: 39927839 Free PMC article.
-
Establishment of a Prognostic Model for Pancreatic Cancer Based on Hypoxia-Related Genes.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241288687. doi: 10.1177/15330338241288687. Technol Cancer Res Treat. 2024. PMID: 39431298 Free PMC article.
References
-
- Fernandez-del Castillo C. In: Clinical Manifestations, Diagnosis, and Staging of Exocrine Pancreatic Cancer. Tanabe K.K., Howell D.A., editors. UpToDate; Waltham, MA, USA: 2016.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials